Drug intelligence / Profile preview

anti-gp49 antibody

Development stage
Preclinical
Lead developer
Tohoku University
Modality
Monoclonal Antibodies → Antibody-Based Therapeutics
Administration
Intraperitoneal
01

Overview

Anti-gp49 antibody is a monoclonal antibody directed against the murine immune checkpoint receptor gp49B, which is the ortholog of human leukocyte immunoglobulin-like receptor B4 (LILRB4/ILT3). The antibody functions by blocking the interaction between gp49B and its physiological ligand, fibronectin (specifically the N-terminal 30-kDa module, FN30). This blockade inhibits gp49B-mediated signaling that contributes to class switch recombination in B cells, thereby reducing the secretion of pathogenic IgG autoantibodies. In preclinical studies using the BXSB/Yaa lupus mouse model, administration of anti-gp49 antibodies has demonstrated efficacy in reducing glomerular deposition and ameliorating autoimmune glomerulonephritis.

Other names
gp49 antibodygp-49 antibodygp 49 antibodyanti-gp49B antibodyanti-gp-49B antibodyanti-gp 49B antibody
02

Targets

LILRB4

Beyond the preview

Go deeper on anti-gp49 antibody.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on anti-gp49 antibody.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call